Last update July 16, 2022
We do not have alternatives for Doxorubicin.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Doxorubicin is also known as
Doxorubicin in other languages or writings:
Doxorubicin belongs to this group or family:
Main tradenames from several countries containing Doxorubicin in its composition:
|Oral Bioavail.||Baja - Low||%|
|VD||(809-1.214 l/m2). 25||l/Kg|
|T½||HCl: 30. Lipos: 70 (24 - 231)||hours|
Write us at firstname.lastname@example.org
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of the caesium variety of Streptomyces peucetius.
Doxorubicin and its active metabolite doxorubicinol are excreted in breast milk in in a small amount, but could be significant. (Damoiseaux 2022, Codacci 2019, Pistilli 2013, Egan 1985)
A mother with non-Hodgkin's lymphoma treated with 4 cycles of 21 days of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone expressed and discarded milk the first 10 days of each cycle and breastfed the next 10 days before of the next treatment, without problems for the infant. (Hersey 2020)
There are two distinct pharmaceutical forms of doxorubicin, in the form of hydrochloride and in liposomal form, with very different pharmacokinetic profiles (Gabizon 2003). Given the variability in interindividual pharmacokinetics, potential pharmacokinetic changes with co-administration with other medication (EMA 2017, Swenson 2003) and their serious side effects (cardiotoxicity, myelotoxicity and liver toxicity) (Tacar 2013, Danesi 2002), it is prudent not to breastfeed during treatment.
When possible, detection in the milk of each patient to determine the total elimination of the drug would be the best indicator for resuming breastfeeding between two rounds of chemotherapy.
It is known via pharmacokinetics that after 3 elimination half-lives (T½) 87.5% of the drug is eliminated from the body; after 4 T½ 94%, after 5 T½ 96.9%, after 6 T½ 98.4% and after 7 T½ 99%. Plasma drug concentrations in the body are negligible after 7 T½. In general, a period of at least five half-lives may be considered a safe waiting period to return to breastfeeding. (Anderson 2016)
Some chemotherapeutics with antibiotic effects may alter the composition of the microbiota (combination of bacteria or bacterial flora) of the milk and the concentration of some of its components (Urbaniak 2014). This possibly occurs briefly with later recovery, with no harmful effects being reported in breastfed infants.
Women undergoing chemotherapy during pregnancy have lower rates of breastfeeding because they experience difficulties in breastfeeding (Stopenski 2017), needing more support to achieve it.
Given the strong evidence that exists on the benefits of breastfeeding for the development of babies and the health of mothers, it is advisable to evaluate the risk-benefit of any maternal treatment, including chemotherapy, individually advising each mother that wishes to continue with breastfeeding. (Koren 2013).